메뉴 건너뛰기




Volumn 88, Issue 5, 2012, Pages 406-415

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

Author keywords

Caspase; Heat shock protein; Histone deacetylase; Melphalan; Multiple myeloma

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 3; NVP HSP 990; PROTEIN KINASE B; UNCLASSIFIED DRUG;

EID: 84859614874     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01764.x     Document Type: Article
Times cited : (26)

References (34)
  • 1
    • 67049162188 scopus 로고    scopus 로고
    • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    • Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-7.
    • (2009) Blood , vol.113 , pp. 5412-5417
    • Landgren, O.1    Kyle, R.A.2    Pfeiffer, R.M.3
  • 2
    • 63849093676 scopus 로고    scopus 로고
    • Myeloma bone disease: recent advances in biology, diagnosis, and treatment
    • Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009;14:276-83.
    • (2009) Oncologist , vol.14 , pp. 276-283
    • Sezer, O.1
  • 3
    • 51649090583 scopus 로고    scopus 로고
    • Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
    • Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-72.
    • (2008) Leukemia , vol.22 , pp. 1767-1772
    • Jakob, C.1    Sterz, J.2    Liebisch, P.3
  • 4
    • 43549108372 scopus 로고    scopus 로고
    • Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
    • Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-4.
    • (2008) Eur J Haematol , vol.80 , pp. 490-494
    • Kaiser, M.1    Mieth, M.2    Liebisch, P.3
  • 5
    • 39449098165 scopus 로고    scopus 로고
    • Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)
    • Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 2008;314:1082-93.
    • (2008) Exp Cell Res , vol.314 , pp. 1082-1093
    • Hecht, M.1    von Metzler, I.2    Sack, K.3    Kaiser, M.4    Sezer, O.5
  • 6
    • 74049162897 scopus 로고    scopus 로고
    • International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
    • Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
    • (2009) Leukemia , vol.23 , pp. 2210-2221
    • Fonseca, R.1    Bergsagel, P.L.2    Drach, J.3
  • 7
    • 41949130070 scopus 로고    scopus 로고
    • Improved survival in multiple myeloma and the impact of novel therapies
    • Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
    • (2008) Blood , vol.111 , pp. 2516-2520
    • Kumar, S.K.1    Rajkumar, S.V.2    Dispenzieri, A.3
  • 8
    • 70350094381 scopus 로고    scopus 로고
    • International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    • Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23:1716-30.
    • (2009) Leukemia , vol.23 , pp. 1716-1730
    • Palumbo, A.1    Sezer, O.2    Kyle, R.3
  • 9
    • 34548133601 scopus 로고    scopus 로고
    • Bortezomib inhibits human osteoclastogenesis
    • von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34.
    • (2007) Leukemia , vol.21 , pp. 2025-2034
    • von Metzler, I.1    Krebbel, H.2    Hecht, M.3
  • 11
    • 58849160500 scopus 로고    scopus 로고
    • Heat shock protein 90 as a drug target: some like it hot
    • Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
    • (2009) Clin Cancer Res , vol.15 , pp. 9-14
    • Banerji, U.1
  • 12
    • 77749270556 scopus 로고    scopus 로고
    • Hsp90 inhibitors: clinical development and future opportunities in oncology therapy
    • Gao Z, Garcia-Echeverria C, Jensen MR. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 2010;13:193-202.
    • (2010) Curr Opin Drug Discov Devel , vol.13 , pp. 193-202
    • Gao, Z.1    Garcia-Echeverria, C.2    Jensen, M.R.3
  • 14
    • 77949443606 scopus 로고    scopus 로고
    • Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
    • Kaiser M, Lamottke B, Mieth M, et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010;84:337-44.
    • (2010) Eur J Haematol , vol.84 , pp. 337-344
    • Kaiser, M.1    Lamottke, B.2    Mieth, M.3
  • 15
    • 25844519550 scopus 로고    scopus 로고
    • HSP90 and the chaperoning of cancer
    • Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
    • (2005) Nat Rev Cancer , vol.5 , pp. 761-772
    • Whitesell, L.1    Lindquist, S.L.2
  • 16
    • 0029824710 scopus 로고    scopus 로고
    • Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90
    • Jaiswal RK, Weissinger E, Kolch W, Landreth GE. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem 1996;271:23626-9.
    • (1996) J Biol Chem , vol.271 , pp. 23626-23629
    • Jaiswal, R.K.1    Weissinger, E.2    Kolch, W.3    Landreth, G.E.4
  • 17
    • 0037131187 scopus 로고    scopus 로고
    • Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
    • Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
    • (2002) J Biol Chem , vol.277 , pp. 39858-39866
    • Basso, A.D.1    Solit, D.B.2    Chiosis, G.3    Giri, B.4    Tsichlis, P.5    Rosen, N.6
  • 18
    • 0036187476 scopus 로고    scopus 로고
    • TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90
    • Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002;9:401-10.
    • (2002) Mol Cell , vol.9 , pp. 401-410
    • Chen, G.1    Cao, P.2    Goeddel, D.V.3
  • 19
    • 1542298267 scopus 로고    scopus 로고
    • Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
    • Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57.
    • (2004) Cancer Lett , vol.206 , pp. 149-157
    • Workman, P.1
  • 20
    • 20144375312 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    • Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
    • (2005) J Clin Oncol , vol.23 , pp. 1885-1893
    • Grem, J.L.1    Morrison, G.2    Guo, X.D.3
  • 21
    • 84859622377 scopus 로고    scopus 로고
    • inventors; Novartis Pharma AG, assignee. 2-amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-one compounds. US patent 20070123546. 2007 May 31
    • Machajewski T, Shafer C, McBride C, inventors; Novartis Pharma AG, assignee. 2-amino-7, 8-dihydro-6H-pyrido[4, 3-D]pyrimidin-5-one compounds. US patent 20070123546. 2007 May 31.
    • Machajewski, T.1    Shafer, C.2    McBride, C.3
  • 22
    • 79961013560 scopus 로고    scopus 로고
    • Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease
    • Labbadia J, Cunliffe H, Weiss A, et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 2011;121:3306-19.
    • (2011) J Clin Invest , vol.121 , pp. 3306-3319
    • Labbadia, J.1    Cunliffe, H.2    Weiss, A.3
  • 23
    • 33644554220 scopus 로고    scopus 로고
    • The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
    • Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91:248-51.
    • (2006) Haematologica , vol.91 , pp. 248-251
    • Kaiser, M.1    Zavrski, I.2    Sterz, J.3    Jakob, C.4    Fleissner, C.5    Kloetzel, P.M.6    Sezer, O.7    Heider, U.8
  • 24
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
    • Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 25
    • 79952270884 scopus 로고    scopus 로고
    • HDACs link the DNA damage response, processing of double-strand breaks and autophagy
    • Robert T, Vanoli F, Chiolo I, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011;471:74-9.
    • (2011) Nature , vol.471 , pp. 74-79
    • Robert, T.1    Vanoli, F.2    Chiolo, I.3
  • 26
    • 49449105426 scopus 로고    scopus 로고
    • Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    • Stuhmer T, Zollinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
    • (2008) Leukemia , vol.22 , pp. 1604-1612
    • Stuhmer, T.1    Zollinger, A.2    Siegmund, D.3
  • 27
    • 80053948169 scopus 로고    scopus 로고
    • Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma
    • Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
    • (2011) Mol Cancer Ther , vol.10 , pp. 1909-1917
    • Khong, T.1    Spencer, A.2
  • 28
    • 17144377442 scopus 로고    scopus 로고
    • Hsp90 activation and cell cycle regulation
    • Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-6.
    • (2004) Cell Cycle , vol.3 , pp. 1530-1536
    • Burrows, F.1    Zhang, H.2    Kamal, A.3
  • 29
    • 69449095860 scopus 로고    scopus 로고
    • Caspases and kinases in a death grip
    • Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009;138:838-54.
    • (2009) Cell , vol.138 , pp. 838-854
    • Kurokawa, M.1    Kornbluth, S.2
  • 30
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
    • (2008) N Engl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 31
    • 57649158485 scopus 로고    scopus 로고
    • Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment
    • Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82:31-8.
    • (2009) Eur J Haematol , vol.82 , pp. 31-38
    • Heider, U.1    Kaiser, M.2    Mieth, M.3
  • 32
    • 73349115580 scopus 로고    scopus 로고
    • Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
    • Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-9.
    • (2009) J Clin Oncol , vol.27 , pp. 5713-5719
    • Richardson, P.G.1    Weller, E.2    Jagannath, S.3
  • 33
    • 82155178738 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma
    • Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8.
    • (2011) Blood , vol.118 , pp. 5752-5758
    • Moreau, P.1    Avet-Loiseau, H.2    Facon, T.3
  • 34
    • 70549097114 scopus 로고    scopus 로고
    • Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more?
    • Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer 2009;9:897-903.
    • (2009) Nat Rev Cancer , vol.9 , pp. 897-903
    • Kumar, S.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.